中国药物经济学2019，Vol.14Issue(1)：5-10,6.DOI:10.12010/j.issn.1673-5846.2019.01.001
索磷布韦治疗基因1b型慢性丙型肝炎的预算影响分析
Budget Impact Analysis on Sofosbuvir in Treating Gene Type 1b Chronic Hepatitis C
朱鸿飞 1李伟2
作者信息
- 1. 中国药科大学,江苏南京 211198
- 2. 万邦医药,江苏徐州 221000
- 折叠
摘要
Abstract
Objective Using budget impact analysis(BIA) to determine whether Sofosbuvir should be included in the National Reimbursement Drug List (NRDL), and then to explore the necessity of applying BIA to health insurance decision-making. Methods From the perspective of the budget holder of Medicare fund, the 2017 was selected as the baseline year, then this paper analyzed and predicted the expenditure of Medicare fund in the next 5 years when Sofosbuvir entered the NRDLv. Results The final analysis showed that the entry of Sofosbuvir into the NRDL would respectively reduce 130 million, 133 million, 143 million, 156 million and 174 million yuan in the total amount of payment for Medicare fund from 2018 to 2022. Conclusion The entry of Sofosbuvir into the NRDL can effectively relieve the payment pressure of the Medicare fund, and when determining whether a drug should be included in the NRDL, BIA is a appropriate economic approach.关键词
预算影响分析/丙型肝炎/索磷布韦/直接抗病毒药物Key words
Budget impact analysis/Hepatitis c/Sofosbuvir/Direct-acting antivirals分类
医药卫生引用本文复制引用
朱鸿飞,李伟..索磷布韦治疗基因1b型慢性丙型肝炎的预算影响分析[J].中国药物经济学,2019,14(1):5-10,6.
